Literature DB >> 29462414

Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages.

Sathishkumar Baskaran1, Markus Mayrhofer2, Hanna Göransson Kultima2, Tobias Bergström1, Lioudmila Elfineh1, Lucia Cavelier1, Anders Isaksson2, Sven Nelander1.   

Abstract

Background: Primary glioblastoma cell (GC) cultures have emerged as a key model in brain tumor research, with the potential to uncover patient-specific differences in therapy response. However, there is limited quantitative information about the stability of such cells during the initial 20-30 passages of culture.
Methods: We interrogated 3 patient-derived GC cultures at dense time intervals during the first 30 passages of culture. Combining state-of-the-art signal processing methods with a mathematical model of growth, we estimated clonal composition, rates of change, affected pathways, and correlations between altered gene dosage and transcription.
Results: We demonstrate that GC cultures undergo sequential clonal takeovers, observed through variable proportions of specific subchromosomal lesions, variations in aneuploid cell content, and variations in subpopulation cell cycling times. The GC cultures also show significant transcriptional drift in several metabolic and signaling pathways, including ribosomal synthesis, telomere packaging and signaling via the mammalian target of rapamycin, Wnt, and interferon pathways, to a high degree explained by changes in gene dosage. In addition to these adaptations, the cultured GCs showed signs of shifting transcriptional subtype. Compared with chromosomal aberrations and gene expression, DNA methylations remained comparatively stable during passaging, and may be favorable as a biomarker.
Conclusion: Taken together, GC cultures undergo significant genomic and transcriptional changes that need to be considered in functional experiments and biomarker studies that involve primary glioblastoma cells.

Entities:  

Mesh:

Year:  2018        PMID: 29462414      PMCID: PMC6280139          DOI: 10.1093/neuonc/noy024

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  35 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

2.  Genetic heterogeneity in rhabdomyosarcoma revealed by SNP array analysis.

Authors:  Charles Walther; Markus Mayrhofer; Jenny Nilsson; Jakob Hofvander; Tord Jonson; Nils Mandahl; Ingrid Øra; David Gisselsson; Fredrik Mertens
Journal:  Genes Chromosomes Cancer       Date:  2015-10-20       Impact factor: 5.006

3.  Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal Transition.

Authors:  Anna Segerman; Mia Niklasson; Caroline Haglund; Tobias Bergström; Malin Jarvius; Yuan Xie; Ann Westermark; Demet Sönmez; Annika Hermansson; Marianne Kastemar; Zeinab Naimaie-Ali; Frida Nyberg; Malin Berglund; Magnus Sundström; Göran Hesselager; Lene Uhrbom; Mats Gustafsson; Rolf Larsson; Mårten Fryknäs; Bo Segerman; Bengt Westermark
Journal:  Cell Rep       Date:  2016-12-13       Impact factor: 9.423

4.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

5.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

Authors:  Andrea Sottoriva; Inmaculada Spiteri; Sara G M Piccirillo; Anestis Touloumis; V Peter Collins; John C Marioni; Christina Curtis; Colin Watts; Simon Tavaré
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-14       Impact factor: 11.205

6.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

Review 7.  The consequences of tetraploidy and aneuploidy.

Authors:  Zuzana Storchova; Christian Kuffer
Journal:  J Cell Sci       Date:  2008-12-01       Impact factor: 5.285

8.  Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity.

Authors:  Markus Rasmussen; Magnus Sundström; Hanna Göransson Kultima; Johan Botling; Patrick Micke; Helgi Birgisson; Bengt Glimelius; Anders Isaksson
Journal:  Genome Biol       Date:  2011-10-24       Impact factor: 13.583

Review 9.  Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer.

Authors:  Jermaine Coward; Angus Harding
Journal:  Front Oncol       Date:  2014-05-26       Impact factor: 6.244

10.  Case-specific potentiation of glioblastoma drugs by pterostilbene.

Authors:  Linnéa Schmidt; Sathishkumar Baskaran; Patrik Johansson; Narendra Padhan; Damian Matuszewski; Lydia C Green; Ludmila Elfineh; Shimei Wee; Maria Häggblad; Ulf Martens; Bengt Westermark; Karin Forsberg-Nilsson; Lene Uhrbom; Lena Claesson-Welsh; Michael Andäng; Ida-Maria Sintorn; Bo Lundgren; Ingrid Lönnstedt; Cecilia Krona; Sven Nelander
Journal:  Oncotarget       Date:  2016-11-08
View more
  9 in total

1.  Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma.

Authors:  Rachael A Vaubel; Shulan Tian; Dioval Remonde; Mark A Schroeder; Ann C Mladek; Gaspar J Kitange; Alissa Caron; Thomas M Kollmeyer; Rebecca Grove; Sen Peng; Brett L Carlson; Daniel J Ma; Gobinda Sarkar; Lisa Evers; Paul A Decker; Huihuang Yan; Harshil D Dhruv; Michael E Berens; Qianghu Wang; Bianca M Marin; Eric W Klee; Andrea Califano; Daniel H LaChance; Jeanette E Eckel-Passow; Roel G Verhaak; Erik P Sulman; Terry C Burns; Fredrick B Meyer; Brian P O'Neill; Nhan L Tran; Caterina Giannini; Robert B Jenkins; Ian F Parney; Jann N Sarkaria
Journal:  Clin Cancer Res       Date:  2019-12-18       Impact factor: 12.531

Review 2.  The Extracellular Matrix and Biocompatible Materials in Glioblastoma Treatment.

Authors:  Andrei Belousov; Sergei Titov; Nikita Shved; Mikhail Garbuz; Grigorii Malykin; Valeriia Gulaia; Alexander Kagansky; Vadim Kumeiko
Journal:  Front Bioeng Biotechnol       Date:  2019-11-19

Review 3.  Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments.

Authors:  Ricardo Gómez-Oliva; Samuel Domínguez-García; Livia Carrascal; Jessica Abalos-Martínez; Ricardo Pardillo-Díaz; Cristina Verástegui; Carmen Castro; Pedro Nunez-Abades; Noelia Geribaldi-Doldán
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

4.  Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.

Authors:  Elin Almstedt; Emil Rosén; Marleen Gloger; Rebecka Stockgard; Neda Hekmati; Katarzyna Koltowska; Cecilia Krona; Sven Nelander
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 13.029

5.  S645C Point Mutation Suppresses Degradation of EGFR to Promote Progression of Glioblastoma.

Authors:  Wenda Huang; Ling Zou; Zhaonian Hao; Baofeng Wang; Feng Mao; Qiuhong Duan; Dongsheng Guo
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

Review 6.  Glioblastoma, from disease understanding towards optimal cell-based in vitro models.

Authors:  Chiara Boccellato; Markus Rehm
Journal:  Cell Oncol (Dordr)       Date:  2022-06-28       Impact factor: 7.051

7.  Transcriptome Changes in Glioma Cells Cultivated under Conditions of Neurosphere Formation.

Authors:  Natalia S Vasileva; Elena V Kuligina; Maya A Dymova; Yulya I Savinovskaya; Nikita D Zinchenko; Alisa B Ageenko; Sergey V Mishinov; Anton S Dome; Grigory A Stepanov; Vladimir A Richter; Dmitry V Semenov
Journal:  Cells       Date:  2022-10-02       Impact factor: 7.666

8.  Mapping and Quantification of Non-Coding RNA Originating from the rDNA in Human Glioma Cells.

Authors:  Anastasia A Sadova; Natalia S Kupriyanova; Galina V Pavlova
Journal:  Cancers (Basel)       Date:  2020-07-28       Impact factor: 6.639

9.  The Evaluation of Glioblastoma Cell Dissociation and Its Influence on Its Behavior.

Authors:  Veronika Skarkova; Marketa Krupova; Barbora Vitovcova; Adam Skarka; Petra Kasparova; Petr Krupa; Vera Kralova; Emil Rudolf
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.